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Osteogenesis Imperfecta
The Position of Substitution for Glycine by Cysteine in the Triple Helical Domain
of the Proal(I) Chains of Type I Collagen Determines the Clinical Phenotype
Barbra J. Starman,* David Eyre,$' Harry Charbonneau,l Maria Harrylock,l Mary Ann Weis,*
Lester Weiss,11 John M. Graham, Jr.,' and Peter H. Byers* **#
Departments of*Pathology, tOrthopedics, §Biochemistry, and **Medicine, and **the Centerfor Inherited Disease,
University of Washington, Seattle, Washington 98195; I1Henry Ford Hospital, Detroit, Michigan 48202; and
'Child Development Center, Dartmouth University, Hanover, New Hampshire 03755
Abstract
Skin fibroblasts grown from three individuals with osteogen-
esis imperfecta (OI) each synthesized a population of normal
type I collagen molecules and additional molecules that had
one or two al(I) chains that.contained a cysteine residue within
the triple-helical domain, a region from which cysteine nor-
mally is excluded. The patients had very different phenotypes.
One patient with OI type I had a population of al(I) chains in
which glycine at position 94 of the triple helix was substituted
by cysteine; a patient with 01 type III had a population of al(I)
chains in which glycine at position 526 of the triple helix was
substituted by cysteine; and the third patient, with OI type II,
had a cysteine for glycine substitution at position 718 of the
al(I) chain. From all three patients, molecules that contained
two mutant chains formed interchain, intramolecular disulfide
bonds, and although less stable to thermal denaturation than
normal molecules, they were more stable than molecules that
contained only a single mutant chain. These findings indicate
that substitutions for glycine within the triple-helical domain
of the al(I) chain are not invariably lethal and that their phe-
notypic effect largely depends on the nature of the substituting
residue and its location in the chain.
Introduction
Osteogenesis imperfecta (01)1 is a remarkably heterogeneous
disorder with phenotypes that range from lethal in the perina-
tal period to mild, virtually asymptomatic conditions (1, 2). A
variety of molecular defects have been found to cause OI,
including gene rearrangements (3-6), point mutations (7-10),
genomic deletions or splicing mutations that result in deletion
of single exon sequences from the mature mRNA and thus the
protein (1 1, 12), mutations that alter the reading frame in the
gene for either chain oftype I procollagen (I 3),2 and mutations
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that alter the amount of type I procollagen synthesized
(14-16).
The relationship between the nature of the mutation and
the clinical phenotype is only beginning to be explored. It
appears that large rearrangements are likely to be lethal ifthey
are expressed, and that the effect of small deletions may be
determined by their chain location and the domain in the
chain affected. We now present evidence that suggests that
substitutions for glycine in the triple-helical domain of
proal(I) are not always lethal and that the phenotypic effects
of such substitutions depend primarily on the nature of the
substituting residue and its location in the chain.
Methods
Clinical summary
Family 1. The proband was a 21-yr-old woman of normal height who
was active in a variety ofsports and had had several previous fractures.
On examination she was noted to have light blue sclerae but no den-
tinogenesis imperfecta or bone deformity. Her mother and all three
siblings also had light blue sclerae and had had occasional fractures.
None had bone deformity, hearing loss, short stature, or dentinogen-
esis imperfecta. Dermal fibroblasts were grown from the proband and
her mother with appropriate consent.
Family 2. The proband was the second child of healthy noncon-
sanguinous parents from a town of 10,000 inhabitants in Iraq. The
pregnancy was uncomplicated; the child weighed 2.67 kg and was 16.5
in. long at birth. Apgar scores were 8 and 9. The x rays at birth were
remarkable for wormian bones in the skull, gracile bones of the upper
extremities, short, broad, and bowed femurs, and thin bowed tibias
(Fig. 1). At 6 wk the child was bright and alert. There was a triangular
appearance to the face and the sclerae were blue. There had been at
least one long bone fracture since birth. Both the prior pregnancy and a
subsequent pregnancy resulted in normal infants. At 3 yr of age her
height was 281/4 in. and her weight was 7 kg, both below the third
percentile. She had blue sclerae, opalescent dentin, and small, broken
teeth. Her speech was normal and she was at least average in intelli-
gence. She crawled up stairs and on and offfurniture but did not stand
without support. She had bilateral tibial, femoral, and humeral bow-
ing. X rays confirmed the multiple bowing and demonstrated general-
ized-osteopenia. Dermal fibroblasts were grown from skin biopsies of
both parents and ofthe affected infant when the child was 6 wk old; all
biopsies were taken with appropriate consent.
Family 3. The proband was the second child of a nonconsan-
guinous couple whose first child was normal. Ultrasound performed
early in the third trimester identified a fetus with extremely short and
bowed limbs and minimal calvarial mineralization. Elective delivery at
34 wk was performed and the infant died upon delivery. The radiologic
picture was diagnostic of 01 type II, the perinatal lethal form of OI.
Preparation ofprocollagen and collagen
Dermal biopsies were explanted and fibroblasts grown under standard
conditions in DME (Grand Island Biologicals, Grand Island, NY) as
previously described (17). To label collagenous proteins, dermal fibro-
blasts were incubated with 2,3,4,5-[3H]proline (100 Ci/mM) or [35S1-
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Figure 1. Radiograph of the proband in family 2.
There are multiple wormian bones in the skull, the
ribs are thin without evidence of previous fracture,
the femurs are short and bowed, and the tibias are
bowed.
cysteine (1,010 Ci/mM; both from Amersham Corp., Arlington
Heights, IL) under conditions previously described (17, 18). Medium
and cell-layer proteins were harvested separately in the presence of
protease inhibitors (17, 18) and concentrated by ethanol precipitation
(30% vol/vol) after addition of carrier collagen (25 ,Ag/ml; Sigma
Chemical Co., St. Louis, MO). Digestion of procollagen with pepsin
(50 jug/ml; Boehringer Mannheim Biochemicals, Inc., Indianapolis,
IN) was carried out for 2 h at 1 8°C in 0.5 M acetic acid adjusted to pH
2.0 with HCI. The reaction was stopped by the addition of pepstatin
and lyophylization.
Characterization ofcollagen by SDS-PAGE
Proa chains were separated under reducing conditions in 5% acryla-
mide slab gels containing SDS and 2 M urea (17, 19); collagens were
separated in the same gels under nonreducing conditions. In some
experiments proteins separated in one dimension were cleaved in the
gel with cyanogen bromide and the resultant peptides were analyzed by
electrophoresis in a second dimension gel (18).
Determination ofthermal stability
Thermal stability of pepsin-digested procollagens was determined as
previously described ( 17, 18, 20).
Preparation ofsamplefor determination of
partial amino acid sequence
To prepare collagen chains for microsequence analysis, 10 100-mm
dishes (Corning Glass Works, Corning, NY) were grown to confluence
and proteins were labeled with [3H]proline the first day and with [35S]-
cysteine the next day using conditions outlined above except that no
carrier collagen was added to the harvested medium. The medium was
collected, dialyzed into 30 mM Tris-HCl, 20 mM NaCl, 2 M urea, pH
7.6, at 4°C, applied to a DEAE-cellulose column (DE-52, 12 X 150
mm; Whatman Laboratory Products Inc., Clifton, NJ) in the same
buffer, and eluted with a 300-ml linear gradient from 0 to 100 mM
NaCl (21). Type I procollagen was dialyzed into 10 mM NH4HCO3
and lyophylized.
The methods for isolating the fragment ofthe triple-helical domain
of the a 1(I) chain that contained the cysteine residue differed slightly
with each mutation.
In the first family the type I procollagen was cleaved with pepsin,
the cysteine residues in the a chains were modified with 4-vinyl pyri-
dine (22), and the chains were separated by reverse-phase HPLC (23,
24). The a1(I) chains were collected, dried, and then cleaved with
trypsin and the 35S-containing al(I)CB5 peptide was recovered by a
second HPLC step. This peptide was digested with trypsin (sequencing
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grade; Boehringer Mannheim Biochemicals, Inc.) in 0.1 M NH4HCO3
and the resulting 35S-containing fragment was again isolated by re-
verse-phase HPLC. The peptide was then dried and subjected to
Edman degradation using a gas-phase automated microsequencer
(model 470A; Applied Biosystems Inc., Foster City, CA). A portion of
the output at each cycle was analyzed on line for PTH-amino acids
(model 120A online PTH analyzer; Applied Biosystems Inc.) and the
remainder was collected to determine the content of radioactivity by
scintillation counting.
In the second family the cysteines in the isolated proa chains of
type I procollagen were reduced and carboxymethylated with iodoace-
tate after reduction for 4 h in 8 M urea with DTT. Sodium iodoacetate
was added to a final concentration of 20 mM and after 15 min a fresh
aliquot of DTT was added and the sample was dialyzed into 0.1 M
acetic acid before lyophylization. The dried sample was digested with
cyanogen bromide for 24 h and the resulting peptides were separated
by reverse-phase HPLC (see below for details). The tubes that con-
tained aI(I)CB3 were pooled and dried. Purified al(I)CB3 was cleaved
at the single Asn-Gly bond in the peptide with hydroxylamine (25).
The sample was dissolved in water and warmed to 40°C, an equal
volume ofcold 2 M NH2OH, pH 10.5, was added, and the mixture was
incubated at 35°C for 90 min. The sample was then frozen before
separation of the fragments. The new peptides were resolved by HPLC
(see below) and the 35S-containing fragment was identified by liquid
scintillation counting. The labeled fragment was dried and subjected to
automated peptide sequence analysis. For the first eight cleavages 80%
of the sample was committed to identification of PTH-amino acids
and the remainder was monitored by liquid scintillation counting; the
entire sample was counted for products of cleavages 9-29.
After purification of type I procollagen synthesized by the cells
from the patient in family 3, the molecules were cleaved with pepsin
and the cysteine residues in the a chains were reduced with DTT and
alkylated with 4-vinyl pyridine. The chains were cleaved with cyano-
gen bromide and a I (I)CB7 was separated by reverse-phase HPLC. The
peptide was then cleaved with trypsin and the fragment that contained
35S was isolated by reverse-phase HPLC and then subjected to se-
quence determination as above.
Separation ofpeptides by HPLC
Whole a chains and peptides obtained from type I procollagen after
cleavage with cyanogen bromide and cleavage of aI(I)CB3 with hy-
A Familyi B Fami:y 2
droxylamine were dissolved in 1% trifluoracetic acid and separated by
reverse-phase chromatography on C4, C8, or C18 macroporous col-
umns. The starting solvent, A, consisted of 5% (vol/vol) acetonitrile in
0.1% (vol/vol) trifluoroacetic acid. Solvent B consisted of 3:1 (vol/vol)
acetonitrile/n-propanol in 0.1% trifluoroacetic acid. Whole a 1(I)
chains were separated on a Brownlee Aquapore RP-300 column (C8;
25 cm X 4.6 mm; Applied Biosystems Inc.) or a 214TP54 column (C4;
25 cm X 4.6 mm; Vydac, Hesperia, CA) by a gradient of 15-30% B in
50 min. Cyanogen bromide peptides were separated by a linear gra-
dient of 5-15% B in 40 min (al[I]CB5, family 1), or a complex gra-
dient of 8-30% B in 60 min (al[I]CB3, family 2; al[I]CB7, family 3)
on the Brownlee RP-300 column. Hydroxylamine peptides were sepa-
rated by a linear 0-25% B gradient over a period of 40 min. Tryptic
peptides were resolved on the same column using a linear gradient of
0-30% B in 60 min. All column effluents (1 ml/min) were monitored
for absorbance at 220 nm, and for 3H and 35S radioactivity by liquid
scintillation counting.
Results
Cysteine in the aJ(I) chain of type I collagen. Dermal fibro-
blasts cultured from two ofthe three probands (probands from
families 2 and 3) synthesized normal type I procollagen and
type I procollagen whose chains had delayed electrophoretic
mobility when examined by SDS-PAGE under reducing con-
ditions (Fig. 2 A). The delay in mobility was abolished by
incubation of cells in a,a'-dipyridyl to block prolyl and lysyl
hydroxylation (not shown). In the third proband, the individ-
ual from family 1, we did not identify any alteration in mobil-
ity or in the efficiency of secretion oftype I procolla;en. When
the amino- and carboxyl-terminal propeptides of type I pro-
collagen were removed by cleavage with pepsin and the prod-
ucts were examined by SDS-PAGE in the absence ofreduction
of disulfide bonds, there was in each cell strain a band that
migrated between the a1(I) chains and the trimer of a 1(III)
that was not synthesized by control cells or by cells from unaf-
fected family members. The electrophoretic mobilities of the
new band differed slightly with each cell strain. In all three
cases the new chain migrated with chains in the region ofa 1(I)
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' Figure 2. Proa and a chains synthesized by
cells from family 1 (A), family 2 (B), and
the proband in family 3 (C). In each group
proa chains separated under reducing con-
ditions are in the top panel and collagen
- chains separated under nonreducing condi-
tions are in the bottom panel. In the bot-
tom panel of each a new band is visible
that migrates between a I(I) and (al [II1)3;
the mobility of the band differs in each pa-
tient. In A (top panel) the two OI panels
are from the affected mother and one
daughter (the proband); the control (C) is a
nonfamily control. In the bottom panel
S only the proteins synthesized by the daugh-
ter's cells are shown. In B and C, OI, af-
fected; F, unaffected father; M, unaffected
O mother; C, control.
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samples from families 2 and 3 there was a band that migrated
just slower than the normal al(I) (Fig. 2 B). The amount ofthe
abnormal band that remained within the cells differed among
the three cell strains; there was virtually none in the cells from
the proband in family 1 and increasing amounts in the pro-
bands from families 2 and 3, respectively.
Localization ofthe new cysteine residues in aJ (I). To char-
acterize the abnormal bands synthesized by cells from the pro-
bands, we separated the pepsin-treated [3H]proline-labeled col-
lagenous proteins in the first dimension under nonreducing
conditions, cleaved the proteins in the gel with cyanogen bro-
mide, and examined the peptides in a second dimension gel
under nonreducing and reducing conditions. When the pep-
tides were separated under reducing conditions, in each case
the band that migrated between al(I) chains and the (al [III)3
molecules gave rise to the peptides of al(I) (Fig. 3). Under
nonreducing conditions the expected peptides from the new
chain synthesized by cells from the proband in family 1 were
all present but the partial fragment al(I)CB5-8 was missing
(residues 86-401; Fig. 3 A), which suggested that the cysteine
was in the domain of al(I)CB5.
When the peptides from the al(I) dimer synthesized by the
cells grown from the proband in family 2 were separated under
nonreducing conditions all the peptides except al(I)CB3 were
present and an additional band of about the size of a dimer of
al(I)CB3 was evident (Fig. 3 B, left panel). When the peptides
were separated under reducing conditions in the second di-
mension, all the peptides of al(I), including al(I)CB3, were-
seen (Fig. 3 B, right panel). This indicated that the abnormal
molecules synthesized by the proband contained a cysteine
residue in the domain of al(I)CB3 (triple-helical residues
402-551), a region from which cysteine is normally excluded.












The electrophoretic mobility of al(I)CB7, al(I)CB8, and
al(I)CB6 from the dimer were normal; that of al(I)CB3 was
delayed. In contrast, the electrophoretic mobilities of
al(I)CB8 and al(I)CB3 derived from the band that migrated
slightly slower than al(I) were delayed, while those of
al(I)CB7 and al(I)CB6 were normal. These findings suggested
that in this cell strain overmodification extended over a longer
domain in molecules that contained a single mutant chain
than in molecules that contained two mutant chains joined by
a disulfide bond.
To better localize the new cysteine residue in proband 2,
we separated [35S]cysteine-labeled a chains in the first dimen-
sion by SDS-PAGE, cleaved them in the gel with hydroxyl-
amine, and separated the resulting peptides in the second di-
mension. The major cysteine-containing band migrated more
slowly than al(I)CB7 (271 residues) and more rapidly than the
partial cleavage fragment al(I)CB7-6 (463 residues; not
shown). This placed the new cysteine residue in both the
al(I)CB3 fragment (residues 402-551) and the large hydroxyl-
amine fragment (residues 523-980) and located it between
residues 523 and 551.
When the peptides from the al(I) dimer synthesized by
cells from the proband in family 3 were examined under
nonreducing conditions all the peptides except for al(I)CB7
were identified (Fig. 3 C). The peptides from the slowly mi-
grating a1(I) chain all migrated more slowly than those from
the normal chain except for al(I)CB6, the carboxyl-terminal
peptide of the triple-helical domain. These results indicated
that overmodification of the chains in abnormal molecules
began in a 1(I)CB7 and extended to the amino-terminal end of
the molecule and that the new cysteine was situated between
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Figure 3. Cyanogen bromide peptides from the normal and abnormal chains and the a 1(I) dimer synthesized by cells from the probands in
families I (A), 2 (B), and 3 (C). [3H]Proline-labeled procollagen secreted by cells from the proband were digested with pepsin and the a chains
were separated in the first dimension under nonreducing conditions and cleaved in the gel with cyanogen bromide; the peptides were then sepa-
rated in the second dimension under nonreducing conditions. For the right panel in B the peptides were separated under reducing conditions in
the second dimension. The position of the new band in the first dimension gel is marked with an asterisk. A, Peptides from the dimer separated
under nonreducing conditions show no evidence of the partial cleavage fragment al(I)CB5-8. This locates the cysteine in al(I)CB5. B, Under
nonreducing conditions (left panel) a 1 (I)CB3 from the dimer (*) is not seen but a new band is present above al(I)CB5-8 (arrow). Under reduc-
ing conditions al(I)CB3 is present (arrow), although the electrophoretic mobility is slower than that of the normal a l(I)CB3. These findings in-
dicate that the new cysteine is in al(I)CB3. C, Under nonreducing conditions there is a new fragment from the a 1(I) dimer that migrates near
the position of a2(I)CB3-5 and all the peptides with the exception of al(I)CB6 are overmodified. This indicates that the cysteine is located
amino-terminal to al(I)CB6 in the domain of al(I)CB7. A diagrammatic representation of the cyanogen bromide peptides of the triple-helical
domain of the al(I) chain is located below.
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Identification ofsubstituted residues. We then labeled pro-
collagens with [3H]proline and [35S]cysteine, purified type I
procollagen by DEAE-cellulose chromatography, isolated by
HPLC the cysteine-containing fragments created by chemical
and/or enzymatic cleavage, and determined the radioactive
and, when possible, the chemical sequence ofthe fragments. In
this manner we determined that in family 1 the cysteine re-
placed glycine at position 94 of the triple helix of the a1(I)
chain, in proband 2 the cysteine replaced glycine at position
526 of the triple helix of the a1(I) chain, and in proband 3 the
cysteine replaced glycine at position 718 of the triple helix of
the a I(I) chain (Fig. 4). In the collagens synthesized by the
probands in families 1 and 3 the site of the cysteine for glycine
substitutions was revealed by coincident 35S radioactivity and




















I determination of the
11 cysteine-containing
fragments from the pro-
bands in families 1 (A),
2 (B), and 3 (C). The
sequences below each
panel are of the normal
a 1 (I) chains; position 1
300 is the first glycine of the
triple-helical domain. A,
200 °- The radioactivity is not
E corrected for cleavage
efficiency. Each residue
100 was identified as the
PTH derivative, except
that the glycine at posi-
tion 94 in the normal
sequence was identified
as a modified cysteine.
B, The counts in the
peaks are corrected for
92% cleavage efficiency
a at each cycle. For the
first eight turns the
PTH-derived amino
acids were isolated and,
although the levels were
low, alanine in the sec-
ond position, aspartic
acid in the sixth posi-
tion, and alanine in the
eighth position could be identified. The placement of the radiola-
beled proline residues and the directly identified residues confirmed
the identity of the fragment and the isolation of [35S]cysteine at the
fourth cycle and indicated that there had been a cysteine for glycine
substitution at residue 526 of the triple-helical domain of the a (I)
chain. C, Two tryptic peptides were identified for their full length
during sequence analysis. The major sequence contained the residues
in the triple helix of a1(I) from 704 to 725 and the minor sequence
was derived from 421 to 434 of the triple helix of a (I). All residues,
including the modified cysteine at 718, were identified. Each residue
in all three panels is identified by the single letter code: A, alanine; D,
aspartic acid; E, glutamic acid; G, glycine; K, lysine; L, leucine; M,
methionine; N, asparginine; P, proline; Q, glutamine; R, arginine; S,
serine; V, valine; P*, hydroxyproline.
major running sequence for the tryptic peptide. In the peptide
sequences around the mutant site in families 2 and 3 the pro-
line that preceeded the cysteine appeared to be fully hydroxyl-
ated considering the PTH amino acid yield.
Abnormal molecules have a low thermal stability. In all
three cell strains in which there is a cysteine for glycine substi-
tution, the type I procollagen molecules that contained two
abnormal chains (as evidenced by the presence of interchain
disulfide bonds) melted at lower temperatures than control
molecules, but at higher temperatures than those molecules
that contained only a single abnormal chain (Fig. 5). In colla-
gens synthesized by cells from proband 1, molecules that con-
tained the disulfide bonded a I(I) dimer melted between 41
and 42°C, and the abnormal molecules that contained a single
abnormal chain melted between 39 and 40°C; in those from
proband 2, the dimer melted between 40 and 41 °C, and the
molecules that contained a single abnormal chain melted at
- 39.5°C; in those from proband 3, the dimer melted between
37 and 38°C and the molecules that contained a single abnor-
mal chain melted at - 37°C. In each instance the single mu-
tant chain (cysteine labeled) in the abnormal molecules was
susceptible to proteolysis at a lower temperature than the nor-
mal chain (proline labeled) that had become overmodified.
Discussion
We have identified three separate families in which the pres-
ence of a cysteine residue within the triple-helical domain of
the proa 1(I) chain oftype I procollagen results in an 01 pheno-
type. The clinical result of the mutations is strikingly different:
glycine to cysteine at residue 94 ofthe triple helix results in the
mild 01 type I phenotype; glycine to cysteine at residue 526
results in the moderate 01 type III phenotype; and glycine to
cysteine at residue 718 results in the perinatal lethal 01 type II
phenotype.
The marked clinical heterogeneity in 01 has been difficult,
to explain clearly on the basis of biochemical findings. The
mildest dominantly inherited form, OI type I, often results
from mutations that alter the amount of normal type I procol-
lagen secreted by cultured cells (14-16). Rarely, it may result
from deletion of all of a COLlAl allele (Willing, M. C., and
P. H. Byers, unpublished observations), but more commonly
appears to result from a variety of other mutations that affect
the synthesis of proal(I) chains (14-16), the incorporation of
proa 1(I) chains into type I procollagen,2 the rapid intracellular
degradation of abnormal type I procollagen molecules, or evi-
dence of an altered sequence within the telopeptide domain of
the a 1(I) chain (26); linkage of the phenotype to mutations in
both COLlA1 and COL1A2 is consistent with these biochemi-
cal and molecular genetic findings (27, 28).
In most instances the perinatal lethal form, 01 type II,
results from substitutions for single glycyl residues within the
triple helical domain ofa 1(I) or a2(I). These mutations appear
to interfere with the formation of stable triple helix, delay
secretion of molecules that contain mutant chains, alter the
extent of posttranslational modification of all chains in mole-
cules that carry a defective chain (17), interfere with amino-
terminal propeptide cleavage, and result in an abnormal
structure of type I procollagen molecules that may affect fi-
brillogenesis (29). In rare instances the 01 type II phenotype
may result from mutations that result in deletion or insertion
of coding material (3-6).
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a - FigureS. Thermal stability of
X - *A' the collagen molecules synthe-
sized by cells from the pro-
37 3839 40 bands in families 1 (A), 2 (B),
and 3 (C). Proteins analyzed
in each top panel were biosyn-
thetically labeled with [3H]-
proline and those in the bot-
tom were labeled with [35S]-
cysteine. In B, lane 1 of the
top panel contains [35S]-
cysteine-labeled proteins and
" 49t#u" 4-s¢ ^e : lane I of the bottom panel
contains [3H]proline-labeled
{'*i~ ~ ~proteins to confirm the posi-
tion of the cysteine-labeled
±.s;i :'proteins.
Between these extremes lies a large group of individuals
with 01, classified on clinical grounds as either 01 type III
(progressive deforming) or OI type IV (dominantly inherited
with non-blue sclerae and often accompanied by dentinogen-
esis imperfecta) and ranging in severity from mild to moder-
ately severe (1, 2). Relatively few mutations that produce these
disorders have been identified. A 4-bp deletion near the 3' end
of the coding region of the proa2(I) chain that altered the last
12 residues of the chain and prevented its assembly into type I
procollagen molecules produced an OI type III phenotype in
the homozygous state but had little phenotypic effect in the
heterozygotes (13, 30). Deletion of single exons encoding do-
mains near the amino-terminal end of the triple helix of the
proa2(I) chain (11) or near the center of the triple helix (31)
have produced mild-to-moderate phenotypes, as has a substi-
tution of arginine for glycine near the carboxyl-terminal end of
the triple-helical domain of proa2(I) (32). This list, however,
emphasizes the difficulty in providing a cohesive understand-
ing of the genotype-phenotype relationship in the mild-to-
moderate 01 phenotypes.
We think that our findings in the three families studied
here, in addition to the accumulation of mutations rapidly
being identified, begin to help understand some aspects of the
relationships between mutation and phenotype. It is striking
that there is progressive improvement of phenotype as the
same point mutation, substitution of cysteine for glycine,




















The mutant sequences are compiled from the following sources: cysteine for glycine at residues 94, 526, and 718 (this report); 175;3 748 (8);
904 (34); 988 (7). The substitution at 94 procedures the OI type I phenotype; the substitution at 175 produces clinical variability (33) but
largely OI type IV; the substitution at 526 produces 01 type III; the substitutions at 718, 748, 904, and 988 all produce the 01 type II lethal
phenotype.
moves toward the amino-terminal end ofthe triple helix ofthe
proal(I) chain. This movement is accompanied by increased
efficiency of secretion of molecules that contain abnormal
chains, increased thermal stability of those molecules, and de-
creased extent along the molecule in which overmodification
occurs. Because cysteine is normally excluded from the triple-
helical domain of proal(I), substitutions in the chain can be
identified by the formation of an a1(I) chain dimer. Lethal
point mutations have been identified that result in substitu-
tions of cysteine for glycine at positions 988 (7), 904 (33), and
748 (8) in the triple-helical domain, and a milder form results
from substitution for glycine at position 175 (34).3 These fami-
lies fit the generalization that mutations that result in substi-
tution of cysteine for glycine are more severe in their phenoty-
pic consequences when they occur near the carboxyl-terminal
end of the triple-helical domain of proa I(I) than at the
amino-terminal end.
This end-rule or phenotypic gradient for mutations along
the proal(I) chain probably depends on the nature of the sub-
stituting amino acid. We are aware, for example, that substi-
tution of arginine for glycine at positions 391 (9) or 664 (10)
results in a lethal 01 phenotype and that substitution for gly-
cine by arginine at position 154 results in the 01 type III phe-
notype.4
Inspection of the sequence motifs around the lethal and
nonlethal cysteine for glycine substitutions (Table I) does not
clearly identify specific domains which, when altered, produce
lethal phenotypes. For example, the substitutions at 718 and
748 both disrupt the hexapeptide GlyProHypGlyProHyp and
are lethal. The substitution at 988 substitutes a glycine that
succeeds a potentially hydroxylatable prolyl residue and the
substitution is in a region bounded by additional hydroxypro-
line residues. In contrast, the substitution at 904 is in a region
entirely devoid of hydroxyproline and would ordinarily be
3. Hollister, D., personal communication.
4. Pruchno, C. J., B. J. Starman, and P. H. Byers, unpublished obser-
vations.
considered a relatively loose triple-helical domain. The non-
lethal substitutions at 94 and 175 are in regions that are not
rich in hydroxyproline and would probably be considered in-
termediate in stability. The substitution at 526 succeeds a hy-
droxylatable prolyl residue and is embedded in a region of
moderate hydroxyproline content; if hydroxyproline content
alone determined the phenotype, then this would be consid-
ered a candidate for a lethal mutation. Given these consider-
ations, it appears that the nature of the substitution and its
location in the chain are the major determinants of the phe-
notypic outcome of a point mutation. Because cysteine resi-
dues in the triple-helical domains of fibrillar collagens, in con-
trast to other substitutions, have the potential for covalent
interactions with other molecules within the cell and in the
matrix, cysteine substitutions may differ in their effects from
those of other residues.
The prolyl residues that preceded the new cysteines in the
abnormal a1(I) chains synthesized by cells from the probands
in family 1 (position 93) and family 3 (position 717) were
hydroxylated. These observations suggest that prolyl 4-hydrox-
ylase may recognize general context as well as specific se-
quence.
The stability to thermal denaturation ofthe chains in mole-
cules that contained one mutant and one normal a1(I) chain
were not equivalent and the first proteolytic cleavage appeared
in the abnormal chain. The sequences around the mutation
sites in each chain we characterized include basic residues that
would be cleaved by the trypsin in the incubation mixture
(Table I). Our observations suggest that the conformation of
the single mutant chain is altered more than that of the two
normal chains and, further, that the disulfide bond created in
molecules with two abnormal chains acts to stabilize those
chains in a less available conformation.
Finally, the findings in family 2 have an additional impor-
tant implication in that they confirm that the OI type III phe-
notype can result from dominant mutations that result in sub-
stitutions for glycine residues in the triple helix of the a 1(I)
chain of type I collagen. Until now, clinical genetic (2, 35) and
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biochemical studies (13) have been interpreted to indicate that
this form of OI is usually inherited in an autosomal recessive
fashion. The findings in this family, additional sequence deter-
mination,4 and our survey of individuals with moderately se-
vere OI phenotypes (Wenstrup, R. J., M. C. Willing, B. J.
Starman, and P. H. Byers, manuscript submitted for publica-
tion) all suggest that a significant proportion of individuals
with the O1 type III clinical phenotype result from dominant
mutations which, in some families, are inherited.
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